B. Riley Has Bullish Outlook for Harrow FY2025 Earnings

Key Points

• B. Riley has raised its FY2025 earnings per share estimate for Harrow, Inc. from $0.56 to $0.88, while also forecasting FY2026 earnings at $2.78 EPS.
• Harrow's recent earnings report showed a significant beat with $0.24 EPS compared to analysts' expectations of $0.01, despite a negative net margin of 4.49%.
• Analysts are optimistic about Harrow, with several firms issuing "buy" ratings and target price increases; the current average price target is $64.67.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Research analysts at B. Riley increased their FY2025 earnings estimates for shares of Harrow in a research note issued to investors on Thursday, August 21st. B. Riley analyst M. Mamtani now expects that the company will earn $0.88 per share for the year, up from their previous forecast of $0.56. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's FY2026 earnings at $2.78 EPS.

A number of other brokerages also recently commented on HROW. William Blair began coverage on shares of Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating for the company. Zacks Research upgraded shares of Harrow from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. BTIG Research upped their price objective on shares of Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Cantor Fitzgerald started coverage on shares of Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 price target on the stock. Finally, HC Wainwright upped their price target on shares of Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $64.67.

Harrow Stock Performance

Harrow stock traded up $0.01 during trading hours on Monday, reaching $39.00. 348,754 shares of the stock were exchanged, compared to its average volume of 671,756. The stock has a market cap of $1.44 billion, a P/E ratio of -156.00 and a beta of 0.41. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. Harrow has a 52-week low of $20.85 and a 52-week high of $59.23. The firm's 50 day moving average is $34.67 and its 200 day moving average is $29.41.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.23. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Harrow

A number of large investors have recently added to or reduced their stakes in HROW. Barclays PLC grew its stake in Harrow by 15.1% in the 4th quarter. Barclays PLC now owns 60,550 shares of the company's stock valued at $2,032,000 after acquiring an additional 7,957 shares during the last quarter. MetLife Investment Management LLC grew its stake in Harrow by 5.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,908 shares of the company's stock valued at $634,000 after acquiring an additional 1,026 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Harrow by 8.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,076 shares of the company's stock valued at $640,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Harrow in the 4th quarter valued at about $78,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.